Promoting Access, Resources and Treatment Through Novel and Equitable Solutions for Cancer Care
PARTNERS
PARTNERS: Promoting Access, Resources and Treatment Through Novel and Equitable Solutions for Cancer Care
1 other identifier
interventional
375
1 country
1
Brief Summary
The purpose of this research is to evaluate a novel, integrated approach to providing navigation services to improve cancer outcomes and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable cancer
Started Jul 2024
Typical duration for not_applicable cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2024
CompletedFirst Posted
Study publicly available on registry
July 1, 2024
CompletedStudy Start
First participant enrolled
July 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2027
September 29, 2025
September 1, 2025
2.9 years
June 24, 2024
September 26, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Participant improvement as measured by participant distress screening tool
Participant distress screening assessment tool is a list of questionnaire with a scale from 0-10, where 0 is none and 10 is extreme distress
4 months
Quality of life as measured by PHQ-9 Patient Depression Questionnaire
Intepretation for PHQ-9 Patient Depression Questionnaire is based on the final score ranging from 1-27, 1-4 is minimal depression, 5-9 is mild, 10-14 is moderate, 15-19 is moderately severe, 20-27 is severe depression
4 months
Secondary Outcomes (2)
The number of social needs as measured by HRSN(Health related social need) questionnaire
4 months
Rate of patient satisfaction as measured by cancer care survey
4 months
Study Arms (1)
Patient Navigation Services
EXPERIMENTALFollowing the consent process, participant will have access to a Patient Navigator, who will serve as a resource for during the time in the study to help navigate and get connected to local resources. The Patient Navigator will keep track of the kinds of support services and referrals provided. The Patient Navigator will contact the participant in 4 months to reassess current needs, quality of life, and areas where additional support is needed.
Interventions
CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
Eligibility Criteria
You may qualify if:
- First, investigators will identify individuals who have either had a cancer screening with a suspicious finding (ie. requires diagnostic follow-up) or those individuals who are referred to the UH Seidman Diagnostic Clinic (led by Co-I Hoehn).
- Within that group, investigators will recruit those who identify as African American, Hispanic, or living in a prioritized geography as defined by zip code ADI\>=75%ile for state
You may not qualify if:
- Any participant who is not willing or able to complete an informed consent form will not be eligible for this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Erika Trapl, PhD
Case Western Reserve University, Case Comprehensive Cancer Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2024
First Posted
July 1, 2024
Study Start
July 30, 2024
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
June 30, 2027
Last Updated
September 29, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- Data is shared with the NPO on a quarterly basis
- Access Criteria
- Data is only shared with the NPO
As a recipient of Merck Foundation funding, investigators are obligated to collect "harmonized metrics" for program participants. This data is shared back (at the individual level) with the National Program Office. There is no PHI in this dataset, and there is no personal identifying information that is shared. The data is not shared beyond the NPO; all data shared by the NPO is aggregated and not identifiable. Additionally, investigator does not intend to share IPD with anyone outside of the NPO